VEDOLIZUMAB
vedolizumab 108 mg/0.68 mL injection, 2 x 0.68 mL pen devices
VEDOLIZUMAB (12638E)
12638E
Manner of administration:Injection
Restriction
Indication: Severe Crohn disease
Treatment phase: Initial 1 (new patient)
Restriction
Indication: Severe Crohn disease
Treatment phase: Initial 2 (change or recommencement of treatment after a break in targeted therapy
of less than 12 months)
Restriction
Indication: Severe Crohn disease
Treatment phase: Initial 3 (recommencement of treatment after a break in targeted therapy of more than
12 months)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 2 | # of repeats: 0 | DPMQ: $1,663.81 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Entyvio | |||||